Back to dashboard
All PlansCoverageLow impact

Bone Turnover Markers for Diagnosis and Management of Osteoporosis and Diseases Associated with High Bone Turnover

Blue Cross & Blue Shield of Mississippi·Endocrinology, Rheumatology, Orthopedics +2 more·Medical Policy
Effective date
Not stated
We identified it
Jun 20, 2026
Days to comply

Summary

This policy confirms that bone turnover markers (including collagen cross links and osteocalcin) are considered investigational and not covered for osteoporosis diagnosis, treatment monitoring, or management of conditions like Paget disease. No recent changes were made - this is a routine policy review with no updates.

Action Required

Action needed
No immediate action required. Continue to deny or obtain prior authorization for CPT codes 82523 (collagen cross links) and 83937 (osteocalcin) as these tests remain investigational and non-covered. Billing team should be aware these codes will likely result in denials.

Affected Billing Codes

82523
83937